Literature DB >> 26623057

Clinicopathological characteristics and prognosis of stage IV colorectal cancer.

Norikatsu Miyoshi1, Masayuki Ohue1, Tatsushi Shingai2, Shingo Noura1, Keijiro Sugimura1, Hirofumi Akita1, Kunihito Gotoh1, Masaaki Motoori1, Hidenori Takahashi1, Kentaro Kishi1, Jiro Okami1, Shigeru Marubashi1, Yoshiyuki Fujiwara1, Masahiko Higashiyama1, Masahiko Yano1.   

Abstract

The aim of this study was to determine the role of curative resection in metastatic colorectal cancer (CRC) and determine the subset of patients who may benefit from concurrent curative resection of primary and metastatic lesions. A total of 103 patients diagnosed with synchronous liver and/or lung metastatic CRC at the Osaka Medical Center for Cancer and Cardiovascular Diseases between 1983 and 2010 were retrospectively investigated. All the patients underwent curative resection of the primary and metastatic lesions. The median follow-up time was 5.69 years. A total of 83 and 13 patients had only liver or lung metastasis, respectively, whereas 7 patients had synchronous liver and lung metastases. A total of 25 patients (24.2%) had no recurrence following curative resection and 14 patients (13.5%) received more than one re-resection for disease recurrence and survived without any further recurrence thereafter. The 5-year survival of liver or lung metastatic CRC was 43.7 or 90.0%, respectively. However, the median overall survival (OS) in patients with synchronous liver and lung metastases was 20.7 months. In the univariate and multivariate analyses, tumour invasion, synchronous liver and lung metastases and time-to-recurrence after the first curative resection were significantly associated with OS and disease-free survival. In conclusion, curative resection confers longer-term survival in patients with liver or lung metastatic CRC.

Entities:  

Keywords:  colorectal cancer; distant metastasis; liver metastasis; lung metastasis; metastatic cancer

Year:  2015        PMID: 26623057      PMCID: PMC4534880          DOI: 10.3892/mco.2015.598

Source DB:  PubMed          Journal:  Mol Clin Oncol        ISSN: 2049-9450


  16 in total

1.  Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer.

Authors:  Toshiaki Watanabe; Michio Itabashi; Yasuhiro Shimada; Shinji Tanaka; Yoshinori Ito; Yoichi Ajioka; Tetsuya Hamaguchi; Ichinosuke Hyodo; Masahiro Igarashi; Hideyuki Ishida; Megumi Ishiguro; Yukihide Kanemitsu; Norihiro Kokudo; Kei Muro; Atsushi Ochiai; Masahiko Oguchi; Yasuo Ohkura; Yutaka Saito; Yoshiharu Sakai; Hideki Ueno; Takayuki Yoshino; Takahiro Fujimori; Nobuo Koinuma; Takayuki Morita; Genichi Nishimura; Yuh Sakata; Keiichi Takahashi; Hiroya Takiuchi; Osamu Tsuruta; Toshiharu Yamaguchi; Masahiro Yoshida; Naohiko Yamaguchi; Kenjiro Kotake; Kenichi Sugihara
Journal:  Int J Clin Oncol       Date:  2011-10-15       Impact factor: 3.402

2.  Comparison of clinicopathological characteristics and prognosis between early and late recurrence after curative surgery for colorectal cancer.

Authors:  Yuan-Tzu Lan; Shih-Ching Chang; Shung-Haur Yang; Chun-Chi Lin; Huann-Sheng Wang; Jeng-Kai Jiang; Wei-Shone Chen; Tzu-Chen Lin; Shih-Hwa Chiou; Jen-Kou Lin
Journal:  Am J Surg       Date:  2013-11-10       Impact factor: 2.565

3.  Cancer statistics, 2010.

Authors:  Ahmedin Jemal; Rebecca Siegel; Jiaquan Xu; Elizabeth Ward
Journal:  CA Cancer J Clin       Date:  2010-07-07       Impact factor: 508.702

4.  Outcome of surgical resection for recurrent pulmonary metastasis from colorectal carcinoma.

Authors:  Ryu Kanzaki; Masahiko Higashiyama; Kazuyuki Oda; Ayako Fujiwara; Toshiteru Tokunaga; Jun Maeda; Jiro Okami; Koji Tanaka; Tatsushi Shingai; Shingo Noura; Masayuki Ohue; Ken Kodama
Journal:  Am J Surg       Date:  2011-08-06       Impact factor: 2.565

5.  Surgical treatment of hepatic and pulmonary metastases from colon cancer.

Authors:  J R Headrick; D L Miller; D M Nagorney; M S Allen; C Deschamps; V F Trastek; P C Pairolero
Journal:  Ann Thorac Surg       Date:  2001-03       Impact factor: 4.330

6.  Stochastic theory of oncogenesis.

Authors:  D J Derkinderen; O J Boxma; J W Koten; W Den Otter
Journal:  Anticancer Res       Date:  1990 Mar-Apr       Impact factor: 2.480

7.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Authors:  Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

8.  Prognostic factors influencing the survival of patients with colon cancer receiving adjuvant 5-FU treatment.

Authors:  M Kornmann; A Formentini; C Ette; D Henne-Bruns; M Kron; S Sander; W Baumann; E-D Kreuser; L Staib; K H Link
Journal:  Eur J Surg Oncol       Date:  2008-03-03       Impact factor: 4.424

9.  An update and our experience with metastatic liver disease.

Authors:  Mahim Koshariya; Rajan B Jagad; Jun Kawamoto; P Papastratis; H Kefalourous; T Porfiris; Christina Tzouma; N J Lygidakis
Journal:  Hepatogastroenterology       Date:  2007-12

10.  Phase II study of neoadjuvant 5-FU + leucovorin + CPT-11 in patients with resectable liver metastases from colorectal adenocarcinoma.

Authors:  Oliver F Bathe; Scot Dowden; Francis Sutherland; Elijah Dixon; Charles Butts; David Bigam; Barb Walley; Dean Ruether; Scott Ernst
Journal:  BMC Cancer       Date:  2004-07-10       Impact factor: 4.430

View more
  9 in total

1.  Function of the macrophage-capping protein in colorectal carcinoma.

Authors:  Wei Wu; Jingdi Chen; Qianshan Ding; Sheng Yang; Jianping Wang; Honggang Yu; Jun Lin
Journal:  Oncol Lett       Date:  2017-09-06       Impact factor: 2.967

2.  Prognostic value of distant metastasis sites and surgery in stage IV colorectal cancer: a population-based study.

Authors:  Dakui Luo; Qi Liu; Wencheng Yu; Yanlei Ma; Ji Zhu; Peng Lian; Sanjun Cai; Qingguo Li; Xinxiang Li
Journal:  Int J Colorectal Dis       Date:  2018-06-21       Impact factor: 2.571

3.  Novel prognostic prediction models for patients with stage IV colorectal cancer after concurrent curative resection.

Authors:  N Miyoshi; M Ohue; M Yasui; S Noura; T Shingai; K Sugimura; H Akita; K Gotoh; S Marubashi; H Takahashi; J Okami; Y Fujiwara; M Higashiyama; M Yano
Journal:  ESMO Open       Date:  2016-05-23

4.  Prognostic and predictive values of tumour budding in stage IV colorectal cancer.

Authors:  K Nagata; E Shinto; M Yamadera; T Shiraishi; Y Kajiwara; K Okamoto; S Mochizuki; K Hase; Y Kishi; H Ueno
Journal:  BJS Open       Date:  2020-05-29

5.  Metastatic patterns and survival outcomes in patients with stage IV colon cancer: A population-based analysis.

Authors:  Jiwei Wang; Song Li; Yanna Liu; Chunquan Zhang; Honglang Li; Bin Lai
Journal:  Cancer Med       Date:  2019-11-06       Impact factor: 4.452

6.  Impact of multidisciplinary tumour boards (MTB) on the clinicopathological characteristics and outcomes of resected colorectal liver metastases across time.

Authors:  Lionel Chen; Nicholas L Syn; Brian K P Goh; Peng Chung Cheow; Prema Raj; Yexin Koh; Alexander Chung; Ser Yee Lee; London Lucien Ooi; Chung Yip Chan; Jin Yao Teo
Journal:  World J Surg Oncol       Date:  2020-09-03       Impact factor: 2.754

7.  Prognostic value of regional lymph node involvement in patients with metastatic colorectal cancer: palliative versus curative resection.

Authors:  Ya-Ting Kuo; Wen-Sy Tsai; Hsin-Yuan Hung; Pao-Shiu Hsieh; Sum-Fu Chiang; Cheng-Chou Lai; Yih-Jong Chern; Yu-Jen Hsu; Jeng-Fu You
Journal:  World J Surg Oncol       Date:  2021-05-13       Impact factor: 2.754

8.  Survival benefit of primary and metastatic tumor resection for colon cancer with liver metastases: A population based, propensity score-matched study.

Authors:  Yunfeng Qiao; Yunfeng Qiao; Huijun Li; Jinge Fu; Shuping You
Journal:  Front Surg       Date:  2022-08-30

9.  CBX8 and CD96 Are Important Prognostic Biomarkers of Colorectal Cancer.

Authors:  Xin Song; Tao Tang; Chaofeng Li; Xin Liu; Lei Zhou
Journal:  Med Sci Monit       Date:  2018-11-01
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.